Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
As of September 18, 2026, Ajanta Pharma's stock closed at ₹3563.6. The stock has shown varied returns over different periods: a 2% return in the last day, a 1% return over 10 days, a -4% return in the last month, a 16% return in the last 3 months, and a 17% return in the last 6 months. Year-to-date, the return is 21%, and since the start, it's 19%. Over the last year, the stock has returned 40%. Technically, the daily trend shows the closing price (₹3563.6) is above the 20-day Exponential Moving Average (EMA) of ₹3533.3 and the 50-day EMA of ₹3476.38. The Supertrend indicator is 'bullish' at ₹3460.07. The monthly trend also indicates a 'bullish' Supertrend at ₹2439.53, with the closing price above both the 20-day EMA (₹2981.35) and 20-day Simple Moving Average (SMA) (₹2835.81). The weekly trend shows a 'bullish' Supertrend at ₹3106.73, with the closing price above the 20-day EMA (₹3343.17) and 50-day SMA (₹2964.1).
Ajanta Pharma has scheduled two investor meetings in September 2026. The first is a one-on-one meeting at the Jefferies India Forum in New Delhi on September 16, 2026. The second is participation in the PL Capital Mid & Small Cap Conference 2026 at Trident, BKC, on September 28, 2026. Both events are scheduled to commence at 09:00. The company has stated that discussions will be based solely on previously published information.
Ajanta Pharma Limited published a notice on August 28, 2026, regarding the transfer of unclaimed dividends and shares to the Investor Education and Protection Fund (IEPF). This action is in accordance with Section 124(6) of the Companies Act, 2013, for shareholders who have not claimed their amounts for the past seven years. The notice invites claims before the shares are transferred. This filing was part of announcements made on August 31, 2026.
As of 18 Sept 2026, 03:30 pm
Showing 3 of 14 candles
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Downward price movement of 2.62 standard deviations recorded on 2026-09-01.
Unusual market activity that may warrant review of the underlying price, volume, or news context.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | PEAK₹1,625.96 crore | ₹1,421.64 crore | ₹1,374.84 crore | ₹1,353.73 crore | ₹1,302.65 crore |
| Other Expenses | PEAK₹493.42 crore | ₹442.70 crore | ₹375.82 crore | ₹392.08 crore | ₹372.52 crore |
| Tax Expense | PEAK₹112.58 crore | ₹80.41 crore | ₹84.83 crore | ₹80.62 crore | ₹75.79 crore |
| Finance Costs | ₹3.18 crore | ₹2.36 crore | ₹5.10 crore | ₹3.39 crore | PEAK₹5.26 crore |
| Profit Before Tax | PEAK₹446.80 crore | ₹347.11 crore | ₹358.60 crore | ₹340.81 crore | ₹331.13 crore |
| Basic Earnings Loss Per Share From Continuing And Discontinued Operations | PEAK₹26.75 per share | ₹21.35 per share | ₹21.91 per share | ₹20.83 per share | ₹20.44 per share |
Ajanta Pharma Limited reported revenue from operations of ₹1,625.96 crore for the June 2026 quarter, an increase of 24.8% compared with the same quarter a year ago and 14.4% higher than the preceding March 2026 quarter. Profit before tax grew 34.9% year-on-year to ₹446.80 crore, lifting the PBT margin to 27.5% from 25.4%. Net profit (PBT minus tax) was ₹334.22 crore, up 30.9%.
Revenue from operations reached ₹1,625.96 crore, up from ₹1,302.65 crore in the corresponding quarter last year. Sequential growth, which had been modest in the preceding three quarters—ranging between 1.6% and 3.9%—stepped up sharply to 14.4% in the latest quarter, signalling a pickup in the pace of expansion. The year-on-year increase of ₹323.31 crore (24.8%) was the largest absolute and percentage gain across the reported quarterly periods.
Tax expense rose to ₹112.58 crore from ₹75.79 crore, an increase of 48.5% that exceeded the growth in pre-tax profit. As a result, the effective tax rate moved from 22.9% to 25.2%. This higher tax burden moderated net profit growth: net profit increased 30.9% year-on-year to ₹334.22 crore, compared with the 34.9% rise in profit before tax.
Basic earnings per share (EPS) increased 30.9% to ₹26.75, mirroring net profit growth. Diluted EPS stood at ₹26.72, pointing to negligible dilution from outstanding instruments.
The June 2026 quarter delivered a notable acceleration in revenue, with strong year-on-year and sequential gains. Profit before tax grew faster than the top line, expanding the PBT margin, although a higher effective tax rate trimmed the net profit advance relative to pre-tax profit growth.
Exchange disclosures and regulatory announcements for Ajanta Pharmaceuticals.
Ajanta Pharma Limited, TPL Plastech Limited, and Time Technoplast Limited filed notices on August 31, 2026, regarding the transfer of unclaimed dividends and shares to the Investor Education and Protection Fund (IEPF) for shareholders who failed to claim amounts over the last seven years. Ajanta Pharma's notice was published in newspapers on August 28, 2026, inviting claims before the shares are transferred under Section 124(6) of the Companies Act, 2013. TPL Plastech and Time Technoplast set specific deadlines for share transfers to IEPF on September 22, 2026, and September 22, 2026, respectively, following their respective dividend announcements for the 2025-26 financial year.
Ajanta Pharma informed stock exchanges on 31st August 2026 of its schedule for analyst/institutional investor meetings: a one-on-one at the Jefferies India Forum in New Delhi on 16th September 2026, and participation in the PL Capital Mid & Small Cap Conference 2026 at Trident, BKC on 28th September 2026. The company confirmed discussions will be based solely on already published information.
Ajanta Pharma Limited announced two institutional investor meetings scheduled for September 2026, with the first event set for September 16 at Oberoi, New Delhi, and the second on September 28 at Trident, BKC. The company will hold one-to-one physical meetings with Jefferies India Forum and PL Capital Mid & Small Cap Conference 2026 respectively, both commencing at 09:00. Rajeev Agarwal is designated as the contact person for these engagements.
NAME OF PROMOTER(S) OR PACS WITH HIM : Ravi P Agrawal, trustee Ravi Agrawal Trust
Ajanta Pharma Limited will hold investor meetings on August 11, 2026, and August 13, 2026, in Singapore & Hongkong with Nuvama India Conference 2026. Additionally, a meeting is scheduled for August 18, 2026, in Mumbai with Motilal Annual Global Conference.
Ajanta Pharma Limited will hold investor meetings on August 11-13, 2026, in Singapore and Hong Kong for the Nuvama India Conference 2026, and on August 18, 2026, at Grand Hyatt, Santacruz for the Motilal Annual Global Conference. Discussions will be based on publicly available information.
Ajanta Pharma Limited has uploaded the written transcript of its earnings call held on July 30, 2026. The transcript, pertaining to the first quarter of the 2026-27 fiscal year, is available on the company's website.
Ajanta Pharma Limited has disclosed the transcripts of its Q1 (Apr-Jun) 2026-27 earnings call on August 3, 2026. The call took place on July 30, 2026, concluding at 17:08:00. The company had previously intimated the exchange about this call on July 20, 2026.
Recent market and company developments associated with Ajanta Pharmaceuticals.
Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance.
Sensex and Nifty 50 are set to open lower due to mixed global cues. Brent crude prices have risen amid US-Iran conflict tensions, raising concerns over energy supplies. Analysts suggest cautious trading with key levels for Nifty 50 and Bank Nifty indicating potential selling pressure.
Sensex gained 114 points while Nifty fell over 40 points on expiry day, reflecting divergent benchmark moves. Softer inflation supported sentiment, but elevated crude prices and geopolitical risks kept investors cautious, with Nifty remaining rangebound between key technical levels.
Q1 Results LIVE Updates: Bajaj Finance, M&M and Tata Steel are the three Nifty results for the day, along with broader market names like Hyundai Motor, Vedanta, Vedanta Aluminium, Swiggy, Mazagon Dock, Torrent Pharma, Thermax and many others. Eicher Motors, Dabur, three Vedanta demerged units, Bajaj Housing, Hexaware and many more also react to numbers. Watch this space for all the LIVE Q1 results updates.
Sensex Today | Stock Market LIVE Updates: Today is the monthly expiry of the Sensex contracts. 24,000 on the downside is key for the Nifty, while the July 17 high of 24,367 is the first hurdle to cross on the upside
Q1 Results Today, 30th July 2026 Live Updates: Stay tuned for more from businessline
Sensex, Nifty, Stock Price Live Updates: Indian benchmark indices traded in a narrow range on Thursday, with gains in IT stocks led by Persistent Systems, Wipro and Coforge helping offset global uncertainty over the Fed, elevated crude oil prices and geopolitical tensions in West Asia, while investors remained focused on Q1 earnings.
Pharma stocks dipped on July 24 after President Trump announced a phased tariff plan for imported generic medicines, raising concerns for Indian exporters. Abbott India led losses at 3.69%, prompting fears over the future of American production and long-term impacts on stocks.
Comprehensive Section Breakdown for Ajanta Pharmaceuticals
Strategic Vision: Develops, manufactures, and markets pharmaceutical formulations.
• Dedicated R&D center developing formulations, APIs, and analytical methodologies.
• Manufacturing facilities producing finished dosages and APIs under global health authority regulations.
• Ability to develop multiple dosage forms including tablets, capsules, injectables, nasal sprays, and topical creams.
Among the expense items with a year-ago comparison, other expenses rose 32.5% to ₹493.42 crore, faster than the 24.8% revenue growth, while finance costs dropped 39.5% to ₹3.18 crore. The quarter also included other income of ₹70.90 crore.
Cost of materials consumed was ₹296.51 crore, employee benefit expense ₹381.11 crore, and depreciation ₹44.50 crore. The resulting profit before tax of ₹446.80 crore produced a PBT margin of 27.5%, an improvement of roughly 2 percentage points from 25.4% a year earlier. The margin expansion occurred even though other expenses outpaced revenue, aided by the sharply lower finance costs and the other income contribution.
Ajanta Pharma reported a strong Q1 FY27 with consolidated revenue up 25% YoY to Rs. 1,626 cr. and PAT up 31% to Rs. 334 cr. The growth was led by India branded generics (up 24% to Rs. 509 cr.), which outperformed the IPM by 36% due to new launches and volume gains, and US generics (up 57% to Rs. 487 cr.) with 51 products on shelf. Africa branded generics grew 30% to Rs. 295 cr., while Asia declined 16% to Rs. 255 cr. due to war impacts. Management declared an interim dividend of Rs. 32 per share and highlighted a 14% 3-year revenue CAGR, with strategic priorities including new product launches, market share gains, and field force productivity enhancement.
Category: B2B Services
Focuses on specialty therapeutic segments in India with a direct marketing presence. Primary areas include Cardiology, Dermatology, Ophthalmology, and Pain Management.
Category: B2B Services
Serves countries in Asia, Africa, and the Middle East with a localized product portfolio tailored to local healthcare demands.
Category: B2B Services
Focuses on niche and complex formulations in the United States, utilizing a selective commercial strategy.
Category: Supply Chain
Provides anti-malarial products and other essential medicines to institutional buyers and health programs, primarily in Africa.
Core Thesis: The company leverages its R&D and manufacturing capabilities to launch differentiated and first-to-market products across various geographic segments.
• Product Differentiation: Focuses on launching differentiated and first-to-market products to address specific patient needs and therapeutic gaps. • Geographic Diversification: Operates across India, emerging markets, and the USA, tailoring product portfolios to local demands. • Integrated R&D and Manufacturing: Maintains a dedicated R&D center and multiple manufacturing facilities adhering to global quality standards.